Monopar Therapeutics Overview

  • Founded
  • 2014
Founded
  • Status
  • Public
  • Employees
  • 10
Employees
  • Stock Symbol
  • MNPR
Stock Symbol
  • Investments
  • 1
  • Share Price
  • $6.03
  • (As of Monday Closing)

Monopar Therapeutics General Information

Description

Monopar Therapeutics Inc is a United States-based clinical-stage biopharmaceutical company. It is focused on developing proprietary therapeutics designed to improve clinical outcomes for cancer patients. The company's product pipeline comprises Validive, Camsirubicin, and MNPR-101.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly Angel backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
  • 1000 Skokie Boulevard
  • Suite 350
  • Wilmette, IL 60091
  • United States
+1 (847) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Monopar Therapeutics Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$6.03 $6.30 $4.28 - $17.01 $75.8M 12.6M 88.3K -$0.64

Monopar Therapeutics Financials Summary

In Thousands,
USD
TTM 31-Mar-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 61,178 52,227 168,493
Revenue 0 0 0 0
EBITDA (7,145) (6,386) (4,324) (3,331)
Net Income (7,098) (6,305) (4,225) (3,228)
Total Assets 25,907 16,869 13,352 7,318
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Monopar Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Monopar Therapeutics‘s full profile, request access.

Request a free trial

Monopar Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Monopar Therapeutics‘s full profile, request access.

Request a free trial

Monopar Therapeutics Executive Team (6)

Name Title Board Seat Contact Info
Chandler Robinson MD Chief Executive Officer & Board Member
Kim Tsuchimoto Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Andrew Mazar Ph.D Chief Scientific Officer & Board Member
Christopher Starr Ph.D Co-Founder and Executive Chairman
Andrew Cittadine Chief Operating Officer
You’re viewing 5 of 6 executive team members. Get the full list »

Monopar Therapeutics Board Members (5)

Name Representing Role Since
Andrew Mazar Ph.D Monopar Therapeutics Chief Scientific Officer & Board Member 000 0000
Chandler Robinson MD Monopar Therapeutics Chief Executive Officer & Board Member 000 0000
Christopher Starr Ph.D Monopar Therapeutics Co-Founder and Executive Chairman 000 0000
Christopher Starr Ph.D Monopar Therapeutics Chairman & Board Member 000 0000
Michael Brown Self Board Member 000 0000
To view Monopar Therapeutics’s complete board members history, request access »

Monopar Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Monopar Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Monopar Therapeutics‘s full profile, request access.

Request a free trial

Monopar Therapeutics Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000 00000000000000 14-Nov-2017 000000000000000000 Drug Discovery 00000000 00000000 00
To view Monopar Therapeutics’s complete acquisitions history, request access »